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Random-effects meta-analyses are used to combine evidence of treatment effects from multiple studies.
Since treatment effects may vary across trials due to differences in study characteristics, heterogeneity in
treatment effects between studies must be accounted for to achieve valid inference. The standard model for
random-effects meta-analysis assumes approximately normal effect estimates and a normal random-effects
model. However, standard methods based on this model ignore the uncertainty in estimating the between-
trial heterogeneity. In the special setting of only two studies and in the presence of heterogeneity we inves-
tigate here alternatives such as the Hartung-Knapp-Sidik-Jonkman method (HKSJ), the modified Knapp-
Hartung method (mKH, a variation of the HKSJ method) and Bayesian random-effects meta-analyses with
priors covering plausible heterogeneity values. The properties of these methods are assessed by applying
them to five examples from various rare diseases and by a simulation study. Whereas the standard method
based on normal quantiles has poor coverage, the HKSJ and mKH generally lead to very long, and therefore
inconclusive, confidence intervals. The Bayesian intervals on the whole show satisfying properties and offer
a reasonable compromise between these two extremes.
Key words: Random-effects meta-analysis; Orphan disease; Bayesian statistics; Between-study
heterogeneity; Coverage probability
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1 Introduction
Meta-analyses are used to combine evidence of treatment effects from multiple studies. Since treatment
effects may vary across trials due to some slight differences in study characteristics including study popula-
tions, trial designs, endpoints and standardization of treatments, heterogeneous treatment effects are quite
natural and must be accounted for to achieve valid statistical inferences. Therefore, random-effects meta-
analysis has become the standard to combine treatment effects from several studies when the presence of
between-trial heterogeneity is suspected which is often the case.
The standard model for random-effects meta-analysis assumes approximately normal effect estimates
and a normal random-effects model, the normal-normal hierarchical model (Hedges and Olkin, 1985).
Based on this model, standard inference methods based on normal quantiles to construct confidence inter-
vals for the combined effect ignore the uncertainty in the estimation of the between-study heterogeneity
and they are only valid for large numbers of trials. However, the combination of only a few studies is quite
common (Davey et al., 2011; Turner et al., 2012). This is not only the case in rare diseases, but in this
context it poses a particular challenge since increased levels of heterogeneity are common (Friede et al.,
2015). For instance, in a recent systematic review by Crins et al. (2014) six studies on acute graft rejections
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and three studies on steroid-restistant rejections were combined in random-effects meta-analyses to assess
the efficacy and safety of Interleukin-2 receptor antibodies for immunosuppression following liver trans-
plantation in children. All studies were controlled, but only two were randomised as it is often the case
in paediatrics. Furthermore, there were some differences between the studies with respect to their control
groups and other design characteristics suggesting some degree of between-trial heterogeneity.
For random-effects meta-analyses with few studies methods based on t-distributions have been sug-
gested (Follmann and Proschan, 1999; Hartung and Knapp, 2001a,b; Knapp and Hartung, 2003; Sidik
and Jonkman, 2003). Furthermore, the use of priors covering plausible between-trial standard deviations
has been advocated when dealing with few studies (Spiegelhalter et al., 2004; Friede et al., 2015; Neuen-
schwander et al., 2010; Schmidli et al., 2014).
Here we consider the special case of only two studies which has recently attracted some attention
(Gonnermann et al., 2015). Examples for meta-analyses of two studies include the summary of two pivotal
studies of a clinical development programme (European Medicines Agency (EMEA), 1998, 2001; Inter-
national Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH), 2002). As we will see when discussing several examples below, meta-analyses of two
studies are not uncommon in orphan diseases. For instance, two randomised controlled trials were included
in the systematic review by Crins et al. (2014) and the Cochrane Review by Miller et al. (2012) on Riluzole
in amyotrophic lateral sclerosis (ALS). In the presence of heterogeneity, however, the meta-analysis of only
two studies may be considered an unsolved problem (Gonnermann et al., 2015). Therefore, we assess here
the performance of alternative approaches to real-life examples from rare diseases and by exploring their
charactersistics in an extensive simulation study. Based on these findings we give some recommendations
on how to approach the problem successfully in practice.
The paper is organised as follows. In Section 2 the statistical model is introduced and methods for
frequentist and Bayesian inference are reviewed. Five examples in various rare diseases are presented in
Section 3 before an extensive simulation study is presented in Section 4. In Section 5 we close with a brief
discussion of the findings.
2 Methodology
2.1 Notation and statistical model
Standard meta-analytic models assume either a common (fixed) effect or random effects across studies.
For the latter, the normal-normal hierarchical model (NNHM) is the most popular. At the first level, the
sampling model assumes approximately normally distributed estimates Y1, . . . , Yk for the trial-specific
parameters θ1, . . . , θk
Yj |θj ∼ N(θj , s2j), j = 1, . . . , k. (1)
Here, we will follow the standard assumption which treats the standard errors sj as known, although this
could be relaxed if necessary. At the second level, the parameter model assumes normally distributed study
effects
θj |µ, τ ∼ N(µ, τ2), j = 1, . . . , k. (2)
The between-trial standard deviation τ determines the degree of heterogeneity across studies. If the pa-
rameter of interest is µ (rather than the study effects θj), inference can be simplified by using the marginal
model
Yj |µ, τ ∼ N(µ, s2j + τ2), j = 1, . . . , k. (3)
The two main approaches to infer µ and the nuisance parameter τ are frequentist and Bayesian. If τ were
known, frequentist and Bayesian (with a non-informative prior for µ) conclusions would be analogous. In
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fact, in the frequentist setting
µˆ =
k∑
j=1
wjYj
/ k∑
j=1
wj ∼ N(µ, 1/w+), wj = 1
/(
s2j + τ
2
)
, j = 1, . . . k, (4)
wherewj are inverse-variance (precision) weights, and w+ =
∑k
j=1 wj is the total precision; the respective
variance 1/w+ is important to construct confidence intervals for µ, as shown in Section 2.2. The Bayesian
result (posterior distribution) is
µ|Y1, . . . , Yk ∼ N
(
k∑
j=1
wjYj
/ k∑
j=1
wj , 1/w+
)
. (5)
For unknown τ , this frequentist-Bayesian “equivalence” breaks down, since the two approaches handle
estimation uncertainty for τ differently.
2.2 Frequentist inference
For unknown τ we first consider frequentist methods to infer µ, which comprise two steps.
(1) An estimate τˆ is derived, from which estimated weights wˆj = 1/(s2j + τˆ2) and a corresponding
estimate µˆ in (4) are obtained. Various estimators for τ have been proposed (for an overview see
DerSimonian and Kacker (2007); Rukhin (2012); Veroniki et al. (2015)), the most prominent being
the moment-estimator due to DerSimonian and Laird (DL). Alternatives are the maximum likelihood
(ML) estimator, the restricted maximum-likelihood estimator (REML), and the Paule-Mandel estima-
tor (PM). While these estimates can differ considerably, for the special case of two trials they coincide
(Rukhin, 2012). We will refer to this common estimate
τˆ2 =
(y1 − y2)2 − s21 − s22
2
. (6)
as the DL estimate, whereby negative values are set to zero.
(2) A confidence interval for µ is then derived. Here we will investigate three methods.
(i) The simplest approach, which was proposed in the seminal paper by DerSimonian and Laird
(1986), uses the following normal approximation
(DL) µˆ± σˆµ z(1−α/2), where σˆ2µ = 1
/ k∑
j=1
wˆj , (7)
and zp is the p-quantile of the standard normal distribution. This method is known to be problem-
atic for small k, since it ignores the uncertainty of τˆ and will therefore give too narrow confidence
intervals and inflated type-I errors.
(ii) Various improvements using a t-distribution with k−1 degrees of freedom and alternative estima-
tors for σµ have been proposed (Hartung and Knapp, 2001a,b; Knapp and Hartung, 2003; Sidik
and Jonkman, 2003). The HKSJ confidence interval is given by
(HKSJ) µˆ± σ˜µ tk−1,(1−α/2), where σ˜2µ =
1
k − 1
k∑
j=1
wˆj(yj − µˆ)2
/ k∑
j=1
wˆj , (8)
and tk−1,(1−α/2) is the (1−α/2)-quantile of the Student-t distribution with k− 1 degrees of
freedom. It works well for any number of studies if study-specific standard errors sj are of
similar magnitude. Otherwise, coverage probabilities can be below the nominal level.
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(iii) To address the limitations of the HKSJ method, a modified interval
(mKH) µˆ± σ⋆µ tk−1,(1−α/2), where σ⋆µ = max{σˆµ, σ˜µ} (9)
has been proposed (Ro¨ver et al., 2015). By taking the maximum of σˆµ and σ˜µ, the problems of
undercoverage and occasional counterintuitive results can be resolved.
2.3 Bayesian inference
In the Bayesian framework, uncertainty of τ is automatically accounted for. Inference for µ and τ is
captured by the joint posterior distribution of the two parameters, from which the marginal distribution
of µ is used to derive, for example, point estimates and probability intervals for µ. While automatic,
the approach requires sensible prior distributions for µ and τ . For the main parameter µ, we will use a
noninformative (improper) uniform prior.
For τ , however, the choice of prior is critical, in particular if the number of studies is small (Dias et al.,
2012, 2014; Turner et al., 2015). For the case of two studies and in the absence of relevant external data,
information about between-trial heterogeneity is clearly very small. Therefore, the main feature of the
Bayesian approach is its ability to average over the uncertain between-trial heterogeneity. This requires
a prior distribution for τ that covers plausible between-trial standard deviations. If information about
heterogeneity is weak, the 95% prior interval should capture small to large heterogeneity.
Table 1 Characteristics of the two half-normal priors for log-odds-ratios.
prior median 95%-interval
HN(0.5) 0.337 (0.016, 1.12)
HN(1.0) 0.674 (0.031, 2.24)
What constitues small to large heterogeneity depends on the parameter scale. For example, for log-odds-
ratios (see examples in Section 3), values for τ equal to 0.25, 0.5, 1, and 2 represent moderate, substantial,
large, and very large heterogeneity. We will use two half-normal (HN) prior distributions (Spiegelhalter
et al., 2004) in the examples (Section 3) and the simulation study (Section 4), with scale parameters 0.5
and 1.0; for prior medians and 95%-intervals see Table 1. The HN(0.5) prior captures heterogeneity values
typically seen in meta-analyses of heterogeneous studies, and will therefore be a sensible choice in many
applications. If very large between-trial heterogeneity is deemed possible, the more conservative HN(1.0)
prior may be advised.
3 Applications in rare diseases
3.1 Introductory remarks
In this section we discuss five real-life examples of meta-analyses of two randomized controlled trials
in various rare conditions. The first two are from the literature whereas the other three examples are
based on US Food and Drug Administration (FDA) approvals in orphan diseases for the following drugs:
Romiplostim, Mozobil, and Krystexxa. In neither of these approvals, a formal meta-analysis was presented
in the official documents.
All examples have a binary endpoint comparing a treatment (T) to a control (C). The following normal
approximation on the log-odds-ratio scale
Y = log
(
rT(nC − rC)
rC(nT − rT)
)
, s2 =
1
rT
+
1
nT − rT +
1
rC
+
1
nC − rC (10)
will be used, where r and n denote the number of responders and number of subjects, respectively.
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0.01 1.00 100.00
odds ratio
Spada (2006)
Heffron (2003)
0.28 [ 0.08 , 1.00 ]
0.10 [ 0.03 , 0.32 ]
experimental control
events total events total
14
4
61
36
15
11
20
36
Crins et al. example: steroid−resistant graft rejection
0.16 [ 0.04 , 0.78 ]HNorm(1.00) (tau = 0.59)
0.16 [ 0.05 , 0.49 ]HNorm(0.50) (tau = 0.33)
0.16 [ 0.06 , 0.46 ]DL−Normal (tau = 0.41)
0.16 [ 0.00 , 129.26 ]DL−HKSJ (tau = 0.41)
0.16 [ 0.00 , 129.26 ]DL−mKH (tau = 0.41)
0.10 1.00
odds ratio
Lacomblez (1996)
Bensimon (1994)
0.65 [ 0.48 , 0.89 ]
0.48 [ 0.24 , 0.94 ]
experimental control
events total events total
20
199
77
712
33
90
78
241
Miller et al. example: mortality
0.59 [ 0.18 , 1.74 ]HNorm(1.00) (tau = 0.39)
0.60 [ 0.29 , 1.14 ]HNorm(0.50) (tau = 0.25)
0.62 [ 0.47 , 0.82 ]DL−Normal (tau = 0.00)
0.62 [ 0.14 , 2.69 ]DL−HKSJ (tau = 0.00)
0.62 [ 0.10 , 3.81 ]DL−mKH (tau = 0.00)
0.01 1.00
odds ratio
Study 20030212
Study 20030105
0.13 [ 0.04 , 0.42 ]
0.27 [ 0.09 , 0.80 ]
experimental control
events total events total
11
7
42
41
12
13
21
21
Romiplostim example: rescue medication incidence
0.19 [ 0.04 , 0.80 ]HNorm(1.00) (tau = 0.53)
0.19 [ 0.07 , 0.53 ]HNorm(0.50) (tau = 0.31)
0.19 [ 0.08 , 0.43 ]DL−Normal (tau = 0.00)
0.19 [ 0.00 , 20.80 ]DL−HKSJ (tau = 0.00)
0.19 [ 0.00 , 36.67 ]DL−mKH (tau = 0.00)
1.00 10.00
odds ratio
Study 3102
Study 3101
4.81 [ 2.95 ,  7.84 ]
5.99 [ 3.56 , 10.07 ]
experimental control
events total events total
89
106
150
148
29
53
148
154
Mozobil example: HSC mobilization
5.34 [ 1.80 , 15.95 ]HNorm(1.00) (tau = 0.37)
5.34 [ 2.73 , 10.48 ]HNorm(0.50) (tau = 0.24)
5.33 [ 3.73 , 7.61 ]DL−Normal (tau = 0.00)
5.33 [ 1.33 , 21.36 ]DL−HKSJ (tau = 0.00)
5.33 [ 0.53 , 53.58 ]DL−mKH (tau = 0.00)
0.01 1.00
odds ratio
Study C406
Study C405
7.81 [ 0.94 , 64.96 ]
6.53 [ 0.78 , 54.65 ]
experimental control
events total events total
11
11
43
42
1
1
20
23
Krystexxa example: infusion reaction
7.14 [ 1.04 , 49.15 ]HNorm(1.00) (tau = 0.55)
7.14 [ 1.39 , 36.70 ]HNorm(0.50) (tau = 0.31)
7.14 [ 1.59 , 32.01 ]DL−Normal (tau = 0.00)
7.14 [ 2.30 , 22.18 ]DL−HKSJ (tau = 0.00)
7.14 [ 0.00 , 119543.65 ]DL−mKH (tau = 0.00)
Figure 1 Forest plots for the five examples from rare diseases with various combined estimates of the
treatment effect. The top two rows show the underlying data (numbers of cases and events in experimental
and control groups) and illustrate the resulting estimates with their 95% confidence intervals. The following
rows show the different combined estimates along with the estimated amount of heterogeneity (posterior
medians for the Bayesian approaches).
3.2 Systematic review of Interleukin-2 receptor antibodies in pediatric liver transplanta-
tion (Crins et al., 2014)
Crins et al. (2014) conducted a systematic review of controlled trials providing evidence on the efficacy
and safety of immunosuppressive therapy with Interleukin-2 receptor antibodies (IL-2RA) Basiliximab
and Daclizumab following liver transplantation in children. Six studies were included in a meta-analysis
of acute graft rejections, of which only two were randomized (Heffron 2003, Spada 2006). In both studies
about 80 patients were randomized, with 2:1 allocation in Heffron et al. (2003) and 1:1 allocation in Spada
c© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.biometrical-journal.com
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et al. (2006). For the purpose of illustration we present here a meta-analysis of the two randomised studies
in Figure 1.
Both studies yielded statistically significant results. However, there were some differences in the es-
timated odds ratios resulting in moderate to substantial estimates of the between-trial standard deviation.
Although the two studies were statistically significant, the HKSJ and mKH methods result in confidence
intervals that include the null hypothesis and are extremely wide (0–129 on the odds ratio scale). In con-
trast, the other three meta-analyses yield statistically significant results with the standard method based on
normal quantiles giving the shortest confidence interval.
3.3 Cochrane review of Riluzole in ALS (Miller et al., 2012)
A Cochrane Review of Riluzole for amyotrophic lateral sclerosis (ALS) combined two randomized, placebo
controlled, double-blind trials (Bensimon et al., 1994; Lacomblez et al., 1996) with information on 12-
month mortality in a meta-analysis (Miller et al., 2012). Miller et al. combined the three active doses of
the dose-ranging study by Lacomblez et al. (1996) into one group for the purpose of the presented analy-
sis. Whereas they used relative risks for their analyses we present here the results in terms of odds ratios
(Figure 1).
As with the previous example both studies demonstrated statistically significant effects of the experi-
mental drug over control (see Figure 1). Whereas in the previous example the DL estimate of the between-
trial heterogeneity was positive, here it is zero. In comparison to the Crins et al. (2014) example, here the
HKSJ and the mKH methods are more informative as they are not quite as long. However, they are still
considerably longer than the Bayesian intervals, which appear to be conservative since they include odds
ratios of 1 although the confidence intervals of the individual studies both exclude 1.
3.4 FDA approval in orphan disease: Romiplostim
Romiplostim (Chen et al., 2007) was approved to treat Idiopathic Thrombocytopenic Purpura based on
two 2:1 randomized studies. The two studies, 20030105 and 20030212, enrolled splenectomized and non-
splenectomized patients, but were similar in their designs.
Here we focus on patients requiring rescue medications (a secondary endpoint). Both studies showed
statistically significant odds ratios (ORs): 0.27 (0.09, 0.80) for 20030105 and 0.13 (0.04, 0.42) for 20030212
(Figure 1). The ratio of ORs is 2.12, suggesting that between-trial heterogeneity should be considered.
However, the frequentist estimate τˆ is zero, resulting in a narrow confidence interval for µ. On the other
hand, the HSKJ and mKN intervals are very wide and do not allow sensible conclusions about the treat-
ment effect. The respective Bayesian intervals are much more plausible. Additionally, for both Bayesian
analyses, the posterior medians for τ are smaller than the respective prior medians, indicating that the two
half-normal priors do not unduly favour small homogeneity.
3.5 FDA approval in orphan disease: Mozobil
Mozobil (Yuan et al., 2008) was approved for the mobilization of hematopoietic stem cells in patients
with lymphoma and multiple myeloma. The two 1:1 randomized studies were conducted in two different
indications: 3101 in Non-Hodgkin’s Lymphoma, and 3102 in Multiple Myeloma. However, no differential
treatment effect with respect to the primary endpoint was expected, which justifies a meta-analysis of the
two studies.
Both studies show statistically significant odds ratios (Figure 1). The ratio of the odds ratios is 1.25,
suggesting possibly small between-trial heterogeneity. Unsurprisingly, the frequentist estimate τˆ is zero.
The HKSJ and mKH methods again provide very wide (but fairly different) CIs: the HKSJ method leads
to a conclusive result, whereas the more conservative mKH does not; this is clearly implausible, since both
studies showed highly significant results. The respective Bayesian intervals are much narrower, suggesting
a sensible compromise between the rather extreme (narrow and wide) frequentist counterparts.
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3.6 FDA approval in orphan disease: Krystexxa
For Krystexxa (Davi et al., 2010), two 2:2:1 randomized studies were used for approval. Here, we consider
only one of two treatment arms (approved dose of 8mg every 2 weeks) and analyze a safety endpoint
(infusion reaction). The two studies showed the following ORs: 6.55 (0.78, 54.60) for C405 and 7.77
(0.94, 64.72) for C406 (Figure 1), which suggest an increase in infusion reaction.
In this example, the HKSJ and mKH intervals, which are usually very wide, give completely different
answers. The HKSJ interval is even narrower than the interval based on normal approximations, whereas
the mKH interval is unrealistically wide. The overly narrow HKSJ interval is due to the similar log-odds-
ratios yj (1.88 and 2.05), which lead to a very small estimate σ˜µ = 0.089 in equation (8); the classical
estimate σˆµ = 0.765, which is used for mKH, is dramatically larger.
3.7 Some concluding remarks on the examples
In this section we presented five examples from a range of rare diseases. In each of these, two studies
were combinded in meta-analyses in situations where between-study heterogeneity had to be suspected
to be present. Still the DL estimator for the between-study heterogeneity was zero in four out of the five
examples. Furthermore, the standard approach based on normal quantiles led to the shortest intervals in all
but the Krystexxa example, in which the HKSJ interval was very narrow. Otherwise the HSKJ and mKH
methods yielded overall long to extremely long confidence intervals not conveying useful information on
the size of the treatment effect. This is not surprising, since the 97.5% quantile of a t-distribution with
1 degree of freedom is about 12.7. Although the Bayesian intervals appeared to be conservative, they
led to interpretable results and a sensible compromise between the very short intervals based on normal
quantiles and the often extremly long intervals based on t-quantiles.
4 Simulation study
4.1 Setup
For the simulation study of this section, we used the NNHM of Section 2. Simulations were limited to
the case of two studies. The study sample sizes n1 and n2 were set to 25, 100, or 400, which leads to six
different combinations of (n1, n2). In the following figures (2–4), the first rows show results for equally
sized studies, while the second rows illustrate the imbalanced settings. Standard errors for the estimated
log-odds-ratios Yj were set to 2/
√
n1 and 2/
√
n2. Without loss of generality, µ was set to zero. In terms of
the “relative” amount of heterogeneity I2 (Higgins and Thompson, 2002), the different settings correspond
to I2 ∈ [0.20, 0.80] for τ = 0.2, and to I2 ∈ [0.86, 0.99] for τ = 1.0. The number of simulations, which
were performed using R, was 15 000. Simulation results are shown for the bias of τ estimates, the fraction
of τ estimates equal to zero, the coverage probabilities and the interval lengths for µ.
4.2 Bias in estimators of the between-study heterogeneity τ
Figure 2 shows the bias of τ estimates. The DL estimator tends to overestimate τ if heterogeneity is small
(τ = 0, 0.1). On the other hand, τ will be underestimated for substantial (τ = 0.5) and large (τ = 1)
heterogeneity. The Bayesian estimators (posterior medians) show similar patterns, with the magnitude of
bias depending on the prior. The overestimation under small heterogeneity is obviously more pronounced
for the HN(1.0) than for the HN(0.5) prior, because the former favours larger values of τ . On the other
hand, underestimation of τ only occurs (and is fairly small) if heterogeneity is substantial to large. It should
be noted that, in contrast to the frequentist methods, the Bayesian estimates for τ are less important, since
the inference for µ takes into account the uncertainty of τ via the posterior distribution.
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Figure 2 Bias in estimating the between-study heterogeneity τ in the different simulation settings.
4.3 Fraction of zero τ estimates
Table 2 shows that the DL estimates for τ are often zero even if heterogeneity is substantial (τ = 0.5)
or large (τ = 1.0). This is a well-known problem, which, if not appropriately addressed, results in too
optimistic inferences for µ.
Table 2 Fractions (in %) of heterogeneity estimates turning out as zero.
true heterogeneity τ
n1 / n2 0.0 0.1 0.2 0.5 1.0
25 / 25 68 67 62 47 29
100 / 100 68 63 52 29 15
400 / 400 68 53 34 16 8
25 / 100 68 65 60 41 23
100 / 400 68 61 46 24 13
25 / 400 68 65 59 39 22
4.4 Coverage probabilities and interval lengths for µ
As can be seen from Figure 3, if heterogeneity is small, all methods work well save for the normal approx-
imation (DL-normal), for which the coverage can be below the nominal level even for small heterogeneity
(τ = 0.1). The HKSJ method is known to work well for equally sized studies, but can be problematic for
unequal study sizes and considerable heterogeneity. As can be seen, the modified method (mKH) resolves
this problem. The Bayesian intervals show good coverage in the range of the prior, irrespective of the study
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sizes. For example, under the more optimistic HN(0.5) prior, coverage is reasonable for τ up to 0.5, but
will drop considerably for larger values that are a-priori less likely.
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Figure 3 Coverage of interval estimators in the different simulation settings.
Coverage is obviously linked to interval length: higher coverage generally comes at the price of longer
intervals. Figure 4 shows that this price can be very high. The two frequentist methods with good coverage
(HKSJ, mKH) exhibit exorbitantly long and implausible 95%-intervals, for which practical relevance is
unclear. Interestingly, the Bayesian intervals are much shorter and provide a sensible compromise between
the HSJK or mKH and the DL-normal intervals. These findings are consistent with results of the examples
in Section 3.
5 Discussion
There is a need for random-effects meta-analyses with only two studies, in particular in rare diseases. To
gain insights into the properties of various meta-analytic methods for two trials, in this special case we
considered examples from the area of rare diseases and conducted an extensive simulation study. The sim-
ulations allowed us to assess the coverage probabilities and mean lengths of the confidence and credibility
intervals. The examples led to further insights into the interpretability of results.
We can summarize our findings as follows. The confidence intervals based on normal quantiles do
not have the right coverage and cannot be recommended for use in the case of two studies. The HKSJ
intervals provide good coverage if the standard errors of the treatment effects observed in the two studies
are of similar size. In general, however, the HKSJ intervals are either so wide that they do not allow any
conclusion, or are very narrow. The latter occurs rarely (if the two study estimates are very close, (8)), but
can lead to problematically narrow confidence intervals and unfavourable coverage. This can be fixed by
the ad-hoc modification (mKH), which is in agreement with findings by Ro¨ver et al. (2015). The mKH
method yields generally coverage probabilities in excess of the nominal level, but the intervals are generally
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Figure 4 Mean lengths of confidence / credibility intervals in the different simulation settings.
so wide that they do not allow any meangingful conclusion. In this sense we agree with Gonnermann
et al. (2015) that there is currently no solution for random-effects meta-analysis in the frequentist setting.
However, Bayesian random-effects meta-analyses with a reasonable prior yield interpretable results in our
examples and showed satisfying properties in the simulations. Therefore, the Bayesian intervals appear to
be a reasonable compromise between the extremes of the confidence intervals based on normal quantiles
that suffer from poor coverage and the t-distribution based intervals that tend to be so long that they are
inconclusive. Use of a Bayesian approach of course entails the question of what constitutes sensible prior
information in a given context. This may be argued on the basis of the endpoint in question, i.e., what
is the plausible amount of heterogeneity expected e.g. among log-ORs, as in the motivating examples
above. Otherwise the problem may be to determine what constitutes relevant external data, and how this
information may be utilized to formulate a prior, as was done e.g. by Turner et al. (2012) and Rhodes et al.
(2015).
Here we investigated several meta-analytic methods for two studies, with a focus on rare diseases. While
a definite answer to this challenging problem is under dispute, the proposed Bayesian approach works well
in our examples and simulation settings. The current frequentist methods have severe limitations, which
may be addressed with future research. Until these limitations are resolved, we recommend to meta-analyze
two heterogeneous studies in a Bayesian way using plausible priors.
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